Caribou Biosciences, Inc. (CRBU) has a negative trailing P/E of -1.3, meaning the company is currently unprofitable on a trailing twelve-month (TTM) basis. Trailing earnings yield is -79.13%.
Criteria proven by this page:
Overall SharesGrow Score: 58/100 with 3/7 criteria passed.
| Year | P/E (TTM) | PEG Ratio | P/B Ratio | P/S Ratio | Dividend Yield |
|---|---|---|---|---|---|
| 2019 | -19.3 | 0.00 | 60.48 | 77.98 | - |
| 2020 | -13.2 | -0.29 | -19.26 | 36.52 | - |
| 2021 | -13.6 | 1.30 | 2.34 | 94.75 | - |
| 2022 | -3.8 | -0.08 | 1.27 | 27.57 | - |
| 2023 | -4.1 | 0.26 | 1.15 | 12.27 | - |
| 2024 | -1.0 | -0.05 | 0.57 | 14.37 | - |
| 2025 | -1.0 | 0.28 | 1.22 | 13.31 | - |
| Year | EPS (Diluted) | Revenue | Net Income | Net Margin |
|---|---|---|---|---|
| 2019 | $-0.39 | $5.79M | $-23.43M | -404.8% |
| 2020 | $-0.57 | $12.36M | $-34.31M | -277.6% |
| 2021 | $-1.11 | $9.6M | $-66.92M | -697.3% |
| 2022 | $-1.64 | $13.85M | $-99.42M | -717.8% |
| 2023 | $-1.38 | $34.48M | $-102.07M | -296.1% |
| 2024 | $-1.65 | $9.99M | $-149.11M | -1491.9% |
| 2025 | $-1.59 | $11.16M | $-148.13M | -1327.4% |
| Year | EPS (Avg) | EPS Range | Revenue (Avg) | Revenue Range | Analysts |
|---|---|---|---|---|---|
| 2026 | $-1.23 | $-1.58 – $-0.71 | $22.17M | $5.54M – $55.41M | 4 |
| 2027 | $-1.30 | $-1.35 – $-1.24 | $24.87M | $6.49M – $43.26M | 3 |
| 2028 | $-1.51 | $-1.91 – $-1.15 | $27.39M | $8.57M – $73.87M | 5 |
| 2029 | $-1.74 | $-5.57 – $-0.19 | $73.61M | $23.03M – $198.57M | 1 |
| 2030 | $-1.84 | $-5.89 – $-0.20 | $164.49M | $51.45M – $443.71M | 1 |
